Clinical factors associated with high PD ‐ L1 expression in patients with early‐stage non‐small cell lung cancer
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Shuta Ohara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1) expression. However, it is not always possible to obtain sufficient tumor specimens for biomarker testing before surgery. In this study, we explored clinical factors that can predict high PD‐L1 expression.
Methods
We retrospectively enrolled 340 lung cancer patients who received pulmonary resection between 2014 and 2023 and who had PD‐L1 expression data. Chi‐squared tests and logistic regression analyses were used to identify clinical factors associated with high PD‐L1 status.
Results
Univariable and multivariable analyses revealed that smoking, high maximum standardized uptake value (SUVmax) of 18F‐fluorodeoxyglucose positron emission computed tomography (18F‐FDG PET/CT), and high plasma fibrinogen are independent predictors of high PD‐L1 expression. A predictive score for high PD‐L1 expression (ranging from 0 to 3) was developed based on these parameters. Notably, only 5% of patients with a score of 0 exhibited high PD‐L1 expression, whereas this proportion increased to 53% for patients with a score of 3.
Conclusion
These results showed that plasma fibrinogen, smoking history, and SUVmax are predictors of high PD‐L1 expression, providing a basis for identifying patients expected to benefit from neoadjuvant ICI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
- Department of Thoracic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Kenichi Suda
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ohara, S., Suda, K., Hamada, A., Chiba, M., Ito, M., Shimoji, M., Takemoto, T., Soh, J., & Tsutani, Y. (2024). Clinical factors associated with high PD ‐ L1 expression in patients with early‐stage non‐small cell lung cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15453
Vancouver
Ohara S, Suda K, Hamada A, Chiba M, Ito M, Shimoji M, et al. Clinical factors associated with high PD ‐ L1 expression in patients with early‐stage non‐small cell lung cancer. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15453
BibTeX
@article{Ohara2024,
author = {Ohara, Shuta and Suda, Kenichi and Hamada, Akira and Chiba, Masato and Ito, Masaoki and Shimoji, Masaki and Takemoto, Toshiki and Soh, Junichi and Tsutani, Yasuhiro},
title = {Clinical factors associated with high PD ‐ L1 expression in patients with early‐stage non‐small cell lung cancer},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15453}
}
EUVIMED